Immunized Against the Cytomegalovirus, Renal Transplant Recipient
Conditions
Keywords
Renal transplant, CMV, Test QuantiFERON-CMV
Brief summary
Cytomegalovirus (CMV) infection was observed in over 30% of organ recipients with high morbidity. Moreover, no prophylaxis, 75% R + D-transplanted, 55%, R + D + and D-25% R + develop CMV. The number of available antiviral drugs is reduced and noticeable side effects (neutropenia, renal toxicity) lead to premature discontinuation of therapy or the use of reduced doses that promote non-response to treatment and the emergence of resistance. In case of neutropenia, there are more an increased risk of secondary rejection due to the reduction of immunosuppressive treatment rendered necessary by the haematological reached. Rational use of these molecules is necessary with essential today as the optimal duration of prophylaxis primary issues and the prophylaxis of recurrences in case of CMV infection reported in.
Detailed description
QuantiFERON-CMV ® is a fast and standardized test that evaluates the CMV specific cellular immunity measuring the amount of secreted Interferon gamma (IFN gamma) in plasma by ELISA. It uses more epitopes of proteins including CMV glycoprotein B (gB), protein IE-1 and protein pp65 and protein pp50, which are specific for (human leukocyte antigen) HLA class I. Pretreatment of the sample is simple and plasma can be stored, frozen, for a delayed dose of interferon.
Interventions
BIOLOGICALCMV Infection
Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for. Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV.
Sponsors
University Hospital, Limoges
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Renal transplant recipient * Immunized against the Cytomegalovirus
Exclusion criteria
* Not willing to participate, no health insurance * clinical evidence of active viral infection * renal transplant recipient whose treatment includes induction antilymphocyte antibodies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Predictive values of Cytomegalovirus infection | 1 week | CMV infection defined by a positive ADNémie confirmed on a second sample ideally one week apart. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| No response to treatment | 21 days | Persistence of an active CMV infection defined by a persistent ADNémie for more than 21 days under antiviral treatment. |
Countries
France
Outcome results
None listed